Why the study?
The study aimed to evaluate the risk of stroke and bleeding among patients with AF treated with DOACs despite having anaemia at treatment initiation.
Does baseline anaemia increase the risk of stroke or bleeding in patients with atrial fibrillation treated with DOACs?
Does baseline anaemia increase the risk of stroke or bleeding in patients with atrial fibrillation treated with DOACs?
In patients with atrial fibrillation treated with DOACs, moderate to severe baseline anaemia is associated with an increased 1-year risk of serious GI bleeding, but does not affect the risk of stroke.
Answers are grounded in this paper and cite their sources.
Moderate/severe anaemia was associated with higher serious GI bleeding on DOACs in AF without affecting stroke; hypothesis-generating and should not yet change practice.
AIMS: The aim of this study was to evaluate the risk of stroke and bleeding among patients with atrial fibrillation (AF) treated with direct oral anticoagulants (DOACs) despite anaemia at treatment initiation time. METHODS AND RESULTS: All Danish patients (N = 41 321) diagnosed with incident AF, having a baseline haemoglobin (Hb), and subsequently initiated DOAC therapy between 2012 and 2019 were identified through administrative registry databases. Patients with anaemia were subdivided according to the World Health Organization classification of anaemia and evaluated regarding risk of stroke and composite bleeding endpoint [hospitalization due to urogenital, gastrointestinal (GI), or intracranial bleeding or epistaxis]. Standardized absolute 1-year risks of stroke and composite bleeding endpoint were calculated using multivariable Cox regression analyses. The standardized absolute 1-year risk difference for composite bleeding increased by 0.96% [95% confidence interval (CI) 0.38-1.54] for patients with moderate/severe anaemia compared with patients with no anaemia. This risk was mainly driven by an increase in standardized absolute 1-year risk for serious GI bleeding, which increased by 0.41% (95% CI 0.19-0.63). No significant difference in standardized absolute 1-year bleeding risk was observed among patients with mild anaemia compared with patients with no anaemia 0.36% (95% CI -0.10 to 0.82). No significant difference in standardized absolute 1-year risk of stroke was observed among patients with mild anaemia, -0.16% (95% CI -0.13 to 0.15), and moderate/severe anaemia, -0.47% (95% CI -0.16 to 0.19), compared with patients with no anaemia. CONCLUSION: For AF patients receiving DOACs, moderate/severe anaemia is a risk factor for serious GI bleeding, while stroke risk is the same regardless of whether anaemia was present at baseline or not.
No takes yet. Share an insight, caveat, or question.
Al‐Hussainy et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: